Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose 225Ac-LNC1011 in mCRPC
NCT07117760Phase 2Active, not recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 225Ac-LNC1011 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The First Hospital of Fujian Medical University. Started Apr 2025; status: active, not recruiting.
02
Drugs
225Ac-LNC1011
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07117760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117760.